[1] Tchounga B, Tiam A, Masaba RO, et al. Assessing tuberculosis clinical presentation, diagnosis and treatment outcomes among children under 5 years old: results from a cohort of children with presumptive TB in Cameroon and Kenya. BMJ Public Health, 2025, 2(Suppl 1):e001566. [2] Tchounga B, Tiam A, Masaba RO, et al. Assessing tuberculosis clinical presentation, diagnosis and treatment outcomes among children under 5 years old: results from a cohort of children with presumptive TB in Cameroon and Kenya. BMJ Public Health, 2025, 2(Suppl 1):e001566. [3] Bergman A, Thomas T. Overview of the epidemiology, diagnosis, and clinical care considerations for people living with and at risk for tuberculosis in the United States. Nurs Clin North Am, 2025, 60(3):491-506. [4] Dong H, Feng J, Chang X, et al. Predictive value of systemic immune-inflammatory biomarkers for drug-induced liver injury in hepatitis B virus surface antigen positive tuberculosis patients: A retrospective observational study. Medicine (Baltimore), 2024, 103(45):e40349. [5] Zhang F, Zhang F, Qin M, et al. Alcohol consumption as a risk factor for anti-tuberculosis drug induced liver injury: A systematic review and meta-analysis. Microb Pathog, 2024, 196:107003. [6] Han B, He Y, Zhu M, et al. Association of gene polymorphisms and serum levels of ALAS1 with the risk of anti-tuberculosis drug-induced liver injury. J Clin Pharmacol, 2025, 65(2):197-205. [7] Song L, Xie XY, Sun J, et al. Structural identification and comprehensive comparison ofsaponin-related impurities present in the three different compound glycyrrhizin tablets. J Pharm Biomed Anal, 2023, 229:115287. [8] Lei P, Cao L, ZhangH, et al. Polyene phosphatidylcholine enhances the therapeutic response of oxaliplatin in gastric cancer through Nrf2/HMOX1 mediated ferroptosis. Transl Oncol, 2024, 43:101911. [9] Yin Q, Song X, Yang P, et al. Incorporation of glycyrrhizic acid and polyene phosphatidylcholine in lipid nanoparticles ameliorates acute liver injury via delivering p65 siRNA. Nanomedicine, 2023, 48:102649. [10] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南. 中华肝脏病杂志, 2015, 23(11) : 810-820. [11] 中华医学会结核病学分会, 结核病病理学诊断专家共识编写组. 中国结核病病理学诊断专家共识. 中华结核和呼吸杂志, 2017, 40(6) : 419-425. [12] Lewis JH, Korkmaz SY, Rizk CA, et al. Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis. Expert Opin Drug Saf, 2024, 23(9):1093-1107. [13] Meitei HN, Pandey A, Haobam R. Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury. Mol Biol Rep, 2023, 50(3):2893-2900. [14] Li M, Zhang D, Yang Q, et al. Longitudinal metabolomics of human plasma reveal metabolic dynamics and predictive markers of antituberculosis drug-induced liver injury. Respir Res, 2024, 25(1):254. [15] Petros Z, Tamirat A, Assefa W. Antitubercular drug induced liver injury among tuberculosis patients in central Ethiopia. Sci Rep, 2025, 15(1):31309. [16] Wang L, Wang H, Qi Y. CYP2S1 rs338599 polymorphism confers reduced risk to anti-tuberculosis drug-induced liver injury and may be a novel marker for its risk prediction. J Clin Lab Anal, 2022, 36(6):e24478. [17] Du Y, Gu J, Yang Y, et al. Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury. Int J Tuberc Lung Dis, 2024, 28(1):6-12. [18] Jiang F, Yan H, Liang L, et al. Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. Liver Int, 2021, 41(7):1565-1575. [19] Sukumaran D, Usharani P, Paramjyothi GK, et al. A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and qualityof life. Indian J Tuberc, 2023, 70(3):303-310. [20] He Y, Zheng X, Dang Z, et al. Association of T-cell profiles with disease severity, drug-induced liver injury, and treatment completion in tuberculosis. Clin Respir J, 2025, 19(8):e70114. |